Glioblastomas with an Oligodendroglial Component: A Pathological and Molecular Study

He, Jié; Mokhtari, Karima; Sanson, Marc; Marie, Yannick; Kujas, M.; Huguet, Stéphanie; Leuraud, Pascal; Laurent, Césari; Delattre, Jean‐Yves; Poirier, Jean‐Paul; Hoang-Xuân, Khê

doi:10.1093/jnen/60.9.863

Cited by 127 publications

(95 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Among GBMO cases, loss of heterozygosity (LOH) of 1p and/or 19q (75% of samples), LOH of 10q (58% of samples), EGFR amplification (39% of samples), and TP53 mutation (22.2% of samples) were detected. These molecular alterations are consistent with some but not all previous studies [53,82]. Nevertheless, distinctions between rates of alterations in GBMOs and GBM support this distinct entity.…”

Section: Glioblastoma Multiforme With Oligodendroglioma Componentsupporting

confidence: 92%

Established and emerging variants of glioblastoma multiforme: review of morphological and molecular features

Karsy¹,

Gelbman²,

Shah³

et al. 2012

View full text Add to dashboard Cite

A b s t r a c t Since the recent publication of the World Health Organization brain tumour classification guidelines in 2007, a significant expansion in the molecular understanding of glioblastoma multiforme (GBM) and its pathological as well as genomic variants has been evident. The purpose of this review article is to evaluate the histopathological, molecular and clinical features surrounding emerging and currently established GBM variants. The tumours discussed include classic glioblastoma multiforme and its four genomic variants, proneural, neural, mesenchymal, classical, as well as gliosarcoma (GS), and giant cell GBM (gcGBM). Furthermore, the emerging variants include fibrillary/epithelial GBM, small cell astrocytoma (SCA), GBM with oligodendroglial component (GBMO), GBM with primitive neuroectodermal features (GBM-PNET), gemistocytic astrocytoma (GA), granular cell astrocytoma (GCA), and paediatric high-grade glioma (HGG) as well as diffuse intrinsic pontine glioma (DIPG

show abstract

Section: Glioblastoma Multiforme With Oligodendroglioma Componentsupporting

confidence: 92%

Established and emerging variants of glioblastoma multiforme: review of morphological and molecular features

Karsy¹,

Gelbman²,

Shah³

et al. 2012

View full text Add to dashboard Cite

show abstract

“…The frequency of GB-O in the whole group of glioblastomas has been observed in the range from 4.2% up to 27.2% [17,21,29,38]. In GB-O cases, the frequency of LOH 1p was from 12 to 24%, 19q was from 32 to 43%, and combined 1p/19q was from 22 to 28% [39,40]. In the more recent EORTC/NCIC trial study concerning a large group of 360 GB cases, an oligodendroglial component was found in 15% of all cases but co-deletion of 1p/19q was found in only one case [41].…”

Section: Discussionmentioning

confidence: 96%

Association of loss of heterozygosity with shorter survival in primary glioblastoma patients

Jesionek-Kupnicka

Szybka²,

Potemski³

et al. 2013

pjp

View full text Add to dashboard Cite

Loss of heterozygosity (LOH) co-deletion 1p/19q, MGMT promoter methylation and/or IDH1 mutation generally signify a better prognosis for patients with glioma. However, the influence of 1p/19q co-deletion and the LOH on other chromosomes in primary glioblastoma on survival is still debatable. The aim of our study was to identify LOH on chromosomes 1p, 19q, 9p, 10q, 13q, and 17p, and evaluate their impact either alone or 1p/19q co-deletion or by groups of LOH on the overall survival of 42 primary glioblastoma patients without an oligodendroglial component. These patients were additionally molecularly characterized for EGFR amplification, IDH1 mutations and TP53 mutations. We assessed their influence on the overall survival of glioblastoma patients. LOH in at least one of the loci on all examined chromosomes was detected in 65% of cases and was significantly associated with shorter overall survival (hazard ratio 3.07; 95% CI: 1.29-7.31, p = 0.006). 1p/19q co-deletion was infrequent (7.14%) and had no impact on overall survival. Our results indicate that in primary glioblastoma a specific LOH group analysis may be important for the prognosis. LOH 1p/19q co-deletion is rare in glioblastoma without an oligodendroglial component and has no impact on patient survival.

show abstract

“…Recently, a new concept, glioblastoma with oligodendroglial components, has been proposed based on accumulated evidence that a subset of glioblastoma includes areas with oligodendroglial features, or a subset of oligodendroglioma acquires the morphological features of glioblastoma during malignant progression. 36,37 Steady histopathological analyses may present a clue.…”

Section: Discussionmentioning

confidence: 99%

Anti-Human Olig2 Antibody as a Useful Immunohistochemical Marker of Normal Oligodendrocytes and Gliomas

Yokoo¹,

Nobusawa²,

Takebayashi³

et al. 2004

The American Journal of Pathology

130

102

View full text Add to dashboard Cite

show abstract

Glioblastomas with an Oligodendroglial Component: A Pathological and Molecular Study

Cited by 127 publications

References 32 publications

Established and emerging variants of glioblastoma multiforme: review of morphological and molecular features

Established and emerging variants of glioblastoma multiforme: review of morphological and molecular features

Association of loss of heterozygosity with shorter survival in primary glioblastoma patients

Anti-Human Olig2 Antibody as a Useful Immunohistochemical Marker of Normal Oligodendrocytes and Gliomas

Contact Info

Product

Resources

About